Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/c-MET/c-MET trispecific antibody GB263T

A Fc-enhanced trispecific antibody targeting epidermal growth factor receptor (EGFR) and two different epitopes of hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met/c-met trispecific antibody GB263T simultaneously targets and binds to the extracellular domain of both EGFR and two different epitopes on c-Met expressed on tumor cells, thereby preventing receptor phosphorylation and inducing internalization of EGFR and c-Met. This downregulates the expression levels of both EGFR and c-Met proteins and prevents the activation of both EGFR- and c-Met-mediated signaling pathways. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Synonym:EGFR x cMET x cMET trispecific antibody GB263T
trispecific EGFR/cMET/cMET antibody GB263T
Code name:GB 263T
GB-263T
GB263T
Search NCI's Drug Dictionary